Latest Insider Transactions at Cytosorbents Corp (CTSO)
This section provides a real-time view of insider transactions for Cytosorbents Corp (CTSO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cytosorbents Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cytosorbents Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2021
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,462
+0.71%
|
$21,848
$4.05 P/Share
|
|
Dec 29
2021
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,538
+0.62%
|
$38,152
$4.05 P/Share
|
|
Dec 10
2021
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.66%
|
$25,000
$5.25 P/Share
|
|
Dec 09
2021
|
Edward Raymond Jones Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,161
-3.82%
|
$15,805
$5.22 P/Share
|
|
Dec 09
2021
|
Edward Raymond Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+4.61%
|
$16,000
$4.12 P/Share
|
|
Nov 23
2021
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
4,000
+13.79%
|
$16,000
$4.98 P/Share
|
|
Aug 31
2021
|
Al Kraus Director |
SELL
Open market or private sale
|
Direct |
4,000
-3.1%
|
$36,000
$9.4 P/Share
|
|
Aug 31
2021
|
Al Kraus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.01%
|
$16,000
$4.12 P/Share
|
|
Apr 12
2021
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,450
+11.64%
|
$395,600
$8.99 P/Share
|
|
Apr 12
2021
|
Vincent Capponi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
62,215
+11.74%
|
$497,720
$8.99 P/Share
|
|
Apr 12
2021
|
Phillip P. Chan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,000
+8.56%
|
$576,000
$8.99 P/Share
|
|
Apr 12
2021
|
Efthymios Deliargyris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+17.94%
|
$320,000
$8.99 P/Share
|
|
Dec 31
2020
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,857
+2.31%
|
$39,285
$5.6 P/Share
|
|
Nov 10
2020
|
Al Kraus Director |
SELL
Open market or private sale
|
Direct |
8,000
-6.01%
|
$64,000
$8.0 P/Share
|
|
Nov 10
2020
|
Al Kraus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+5.67%
|
$24,000
$3.45 P/Share
|